Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV-2 pandemic.

Lory, Pauline; Combret, Sandrine; Michot, Joelle; Veyrac, Gwenaelle; Chouchana, Laurent; Grandvuillemin, Aurélie

Lory, Pauline; Combret, Sandrine; Michot, Joelle; Veyrac, Gwenaelle; Chouchana, Laurent; Grandvuillemin, Aurélie.

Afiliação

Lory P; Regional Pharmacovigilance Center, Dijon University Hospital, 21079 Dijon, France.
Combret S; Regional Pharmacovigilance Center, Dijon University Hospital, 21079 Dijon, France.
Michot J; Regional Pharmacovigilance Center, Saint-Antoine Hospital, AP-HP, Sorbonne - Université de Paris, 75013 Paris, France.
Veyrac G; Regional Pharmacovigilance Center, Nantes University Hospital, 44093 Nantes, France.
Chouchana L; Regional Pharmacovigilance Center, Department of Pharmacology, Cochin Hospital, AP-HP, Centre - Université de Paris, 75014 Paris, France.
Grandvuillemin A; Regional Pharmacovigilance Center, Dijon University Hospital, 21079 Dijon, France. Electronic address: aurelie.grandvuillemin@chu-dijon.fr.

Therapie ; 78(4): 419-425, 2023.

Article em En | MEDLINE | ID: mdl-36376122

Palavras-chave

Adverse drug reaction; COVID-19; Lopinavir; Pharmacovigilance; Ritonavir

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Therapie Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google